High stalls in the cryptom market-but 200% US customs bomb can destroy a lot
- Bitcoin (BTC) reached $ 118,000 today because the ETF inflows dry up and the stock market liquidity rises quickly.
- Trumps 200% Import customs on medication would make them $ 51 billion and drastically increase the costs for US patients.
Bitcoin (BTC) exceeded all expectations and climbed over $ 113,000 on July 10 and reached $ 118,403 today. Ethereum followed the swing and was traded over $ 3,000. The strong increase was associated with the growing optimism of the political circles in Washington and the positive mood in the US stock markets.
Institutional investments played an important role in the rally. The tributaries in Bitcoin Spot funds from companies such as Blackrock and Fidelity reached over $ 1.2 billion in early July. Joshua Chu from the Hong Kong Web3 Association found that “the big players buy the offer and dry out the liquidity on the stock exchanges.”
Pharmaceutical industry faces a 51 billion dollar stroke
While the cryptoma markets attract capital, the pharmaceutical sector is faced with a different type of pressure. US President Donald Trump urges one 200 percent taxation of pharmaceutical imports, which puts the affected companies into crisis mode. Although the tariffs can be pushed up by up to 18 months, analysts see little consolation in the grace period. According to UBS experts, the time frame for companies is not realistic to shift their production:
“Usually we would see 4 to 5 years as a time frame for relocating commercial production to a new location.”
Barclays warned on Wednesday that such tariffs could increase production costs and lead to delivery interruptions. A 25 % customs set alone would drive pharmaceutical prices in the United States by around $ 51 billion every year and increase prices for patients by 12.9 %, according to the PHRMA data.
Effects on patients and trade agreements
Afsaneh decided by the Rockcreek Group said in the CNBC program Closing Bell that the situation for consumers could continue to deteriorate. Afsaneh decided:
“That would be potentially catastrophic for everyone, because we need these medicines, and companies take a long time to produce them here in the USA.”
The pharmaceutical sector has traditionally been spared tariffs because it is so important. However, Trump has taken a hard attitude by criticizing the companies for their pricing policy and urging increased production in the USA. Even with the recent efforts of companies such as Sanofi and Eli Lilly to invest on site, the deadlines remain an obstacle.
There is still some hope in the upcoming trade talks. A recent closed agreement Between the United States and Great Britain, a discussion about preferred treatment for British pharmaceuticals, which depends on the results of the Section 232 report expected for the end of July. Similar expectations are awakened in Europe and Switzerland, although companies have no clarity.
No Comments